1
|
Bakheit A, McLellan DL, Burnett ME. Symptomatic and functional improvement of foot dystonia with medial popliteal nerve block. Clin Rehabil 2016. [DOI: 10.1177/026921559601000414] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Affiliation(s)
- Amo Bakheit
- University Rehabilitation Research Unit, Mail Point 874, Level C, West Wing, Southampton General Hospital, Southampton SO16 6YD, UK Southampton
| | - DL McLellan
- University Rehabilitation Research Unit, Southampton General Hospital Southampton
| | - ME Burnett
- University Rehabilitation Research Unit, Southampton General Hospital Southampton
| |
Collapse
|
2
|
Barnes MP, Best D, Kidd L, Roberts B, Stark S, Weeks P, Whitaker J. The use of botulinum toxin type-B in the treatment of patients who have become unresponsive to botulinum toxin type-A -- initial experiences. Eur J Neurol 2006; 12:947-55. [PMID: 16324088 DOI: 10.1111/j.1468-1331.2005.01095.x] [Citation(s) in RCA: 31] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
Abstract
The increasing use of botulinum toxin type-A, especially for focal dystonia and spasticity has highlighted the issue of secondary non-responsiveness. Within the last few years botulinum toxin type-B (Myobloc/Neurobloc) has become commercially available as an alternative to type-A. This paper discusses our initial experience of botulinum toxin type-B in a total of 63 individuals who attended our botulinum clinic. Thirty-six patients had cervical dystonia and a secondary non-response to type-A toxin. Thirteen of these patients (36%) had a reasonable clinical response to Neurobloc and continue to have injections. The other 23 patients either had no response, or a poor response, or had unacceptable side effects and ceased treatment. A small number of people with blepharospasm, hemifacial spasm and foot dystonia also had a disappointing response to injection. Twenty patients with spasticity were also type-A resistant. Seven of these show some continuing response to type-B, without unacceptable side effects. These findings demonstrate that botulinum toxin type-B has a place in the management of patients who have become non-responsive to type-A, but overall the responses to type-B toxin were disappointing.
Collapse
Affiliation(s)
- M P Barnes
- Specialist Neurological Rehabilitation Services Division, Northgate & Prudhoe NHS Trust, Hunters Road, Newcastle-upon-Tyne, UK.
| | | | | | | | | | | | | |
Collapse
|
3
|
Tugnoli V, Eleopra R, Montecucco C, De Grandis D. The therapeutic use of botulinum toxin. Expert Opin Investig Drugs 2005; 6:1383-94. [PMID: 15989508 DOI: 10.1517/13543784.6.10.1383] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/09/2023]
Abstract
Since Alan Scott's research, botulinum toxin (BoNT) has been used in several diseases or conditions characterised by muscular overactivity. BoNT acts on either neuromuscular or autonomic cholinergic junctions. Seven different serotypes are known, with antigenic specificity and different therapeutic profiles. BoNT is made up of a heavy chain, involved in binding and membrane translocation, and a light chain, involved in blocking neuroexcytosis. Each serotype shares a specific acceptor on the presynaptic membrane of a cholinergic junction. The available BoNT preparations differ in toxicity, purity and stability. Injection of the neurotoxin produces several modifications at a neuromuscular junction. Axonal sprouting, muscular fibre atrophy, and new end-plates are the most evident histological events after BoNT treatment. They appear to be reversible in untreated muscles. Diffusion can occur at first by haematogeneous or local BoNT spread. Several factors, such as dose, volume, site of injection, muscle size, and muscular fascia, can influence the amount of diffusion and possible side-effects. After prolonged BoNT treatment patients can become unresponsive. Antibodies directed against BoNT have been observed with ELISA or mouse bioassay. Different serotypes have been used to treat non-responder patients. Novel toxins with lower immunogenicity and prolonged clinical efficacy are required for more effective treatment.
Collapse
Affiliation(s)
- V Tugnoli
- Neurological Department, St Anna Hospital, Corso Giovecca 203, 44100 Ferrara, Italy
| | | | | | | |
Collapse
|
4
|
Arai L, Harding S. A review of the epidemiological literature on the health of UK-born black caribbeans. CRITICAL PUBLIC HEALTH 2004. [DOI: 10.1080/109581590410001725355] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
5
|
Billante CR, Zealear DL, Billante M, Reyes JH, Sant'Anna G, Rodriguez R, Stone RE. Comparison of neuromuscular blockade and recovery with botulinum toxins A and F. Muscle Nerve 2002; 26:395-403. [PMID: 12210370 DOI: 10.1002/mus.10213] [Citation(s) in RCA: 42] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
Intramuscular injection of botulinum toxin A is used to treat focal dystonias. Because immunoresistance has been documented in some patients, other molecular forms of the toxin have been evaluated clinically. The present investigation compared the time course and extent of neuromuscular blockade and recovery of botulinum toxin types A and F using an electromyographic monitoring system implanted in the rat hindlimb. For a given dose, the degree and duration of blockade was more complete with type A toxin. Delayed onset of recovery in animals that received high doses of type A toxin allowed time for denervative changes to prevent a full return to baseline, as confirmed histologically. Conversely, animals receiving type F toxin fully recovered within 30 days at all dose levels. The rapid recovery with type F toxin suggested that neuromuscular transmission was restored via the original terminals rather than through functional collateral sprouting. The reversible nature of blockade with this molecular species puts in question its future clinical utility.
Collapse
Affiliation(s)
- Cheryl R Billante
- Department of Otolaryngology, Vanderbilt Voice Center, 1500 21st Avenue South, Suite 2700, Nashville, TN 37212, USA.
| | | | | | | | | | | | | |
Collapse
|
6
|
Affiliation(s)
- M A Royal
- Pain Evaluation and Treatment, 5801 East 41st, #1000, Tulsa, OK 74135-5618, USA
| |
Collapse
|
7
|
Agbuya PG, Sherman NE, Moen LK. Proteolytic processing of the human T-cell lymphotropic virus 1 reverse transcriptase: identification of the N-terminal cleavage site by mass spectrometry. Arch Biochem Biophys 2001; 392:93-102. [PMID: 11469799 DOI: 10.1006/abbi.2001.2432] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
Human T-cell lymphotropic virus 1 (HTLV-1) is a type C human retrovirus, which is the causative agent of Adult T-cell Leukemia and other diseases. The reverse transcriptase of HTLV-1 (E.C. 2.7.7.49) is synthesized as part of a Gag--Pro--Pol precursor protein, and the mature Gag, Pro, and Pol proteins, including the reverse transcriptase, are created by proteolytic processing catalyzed by the viral protease. The location of the proteolytic cleavage site, which creates the N-terminus of mature HTLV-1 reverse transcriptase, has not been previously identified. By using sequence comparisons of several retroviral polymerases, as well as information about the location of the ribosomal frameshift, we tentatively identified this N-terminal processing site. PCR amplification was used to construct a clone, which spans a region of the pro--pol junction of HTLV-1, to produce a recombinant Pro--Pol protein spanning the locations of those cleavage sites proposed by others as well as the one identified by our sequence alignment. Cleavage of the recombinant Pro--Pol protein by HTLV-1 protease generated a 5.5-kDa fragment. Analysis of this fragment by capillary LC-MS and MS/MS revealed the N-terminal cleavage site to be between Leu(147)--Pro(148) of the pro ORF. This is the first physical identification of the authentic amino acid sequence of the reverse transcriptase of HTLV-1. The data reported here provides a basis for further investigation of the function and structural aspects of protein-nucleic interaction.
Collapse
Affiliation(s)
- P G Agbuya
- Department of Chemistry and Biochemistry, Old Dominion University, Norfolk, Virginia, USA
| | | | | |
Collapse
|
8
|
Affiliation(s)
- H A Khawaja
- Center for Dermatology and Cosmetic Surgery, San Salvador, El Salvador
| | | |
Collapse
|
9
|
Anantharaman V, Moen LK. Effects of Nucleoside Analogs on Native and Site-Directed Mutants of HTLV Type 1 Reverse Transcriptase. Bioorg Chem 2000; 28:293-305. [PMID: 11133148 DOI: 10.1006/bioo.2000.1181] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
A bacterial assay was developed for testing HTLV-1 reverse transcriptase sensitivity to common nucleoside analog inhibitors in an Escherichia coli strain characterized by a temperature sensitive PolI/RecA deletion phenotype. This genetic complementation assay exploits the ability of HTLV-1 reverse transcriptase to functionally replace these missing activities at nonpermissive temperatures. The four inhibitors tested, dideoxyinosine, dideoxyadenosine, deoxythymidine, and didehydrodeoxythymidine are well-known inhibitors of HIV reverse transcriptase. All except dideoxyadenosine showed a strong activity against HTLV-1 reverse transcriptase with IC(50); in the nanomolar range. Sequence alignments were used to identify amino acid residues in HTLV-1 reverse transcriptase, which correspond to those identified as important for drug-resistance in HIV reverse transcriptase. Mutations of some of these HTLV-1 residues altered the IC(50) for the inhibitors as expected, which suggests that these amino acids have a function in HTLV-1 reverse transcriptase similar to that of their homologs in HIV reverse transcriptase. Copyright 2000 Academic Press.
Collapse
Affiliation(s)
- V Anantharaman
- Department of Chemistry and Biochemistry, Old Dominion University, Norfolk, Virginia, 23529-0126
| | | |
Collapse
|
10
|
Affiliation(s)
- F Cardoso
- Department of Neurology, Federal University of Minas Gerais, Belo Horizonte, Brazil
| | | |
Collapse
|
11
|
Denislic M, Pirtosek Z, Vodusek DB, Zidar J, Meh D. Botulinum toxin in the treatment of neurological disorders. Ann N Y Acad Sci 1994; 710:76-87. [PMID: 8154763 DOI: 10.1111/j.1749-6632.1994.tb26615.x] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/29/2023]
Abstract
Botulinum toxin therapy is safe and effective in the treatment of different movement disorders, especially focal dystonias. We reviewed botulinum toxin treatment of 97 patients: 36 had blepharospasm, 41 had torticollis, and 20 had diverse movement disorders. Patients with blepharospasm and torticollis improved markedly after botulinum toxin injections. The most common side effect in BS patients was ptosis (44.4%); in TC patients, it was dysphagia (29.3%). The mean duration of the improvement in both groups was 3.4 months. Very promising results were obtained also in the heterogeneous group including patients with other focal dystonias and cerebral palsy. On the basis of these results, we concluded that BTA injections must now be considered the mainstay of therapy for focal dystonias and other involuntary movement disorders.
Collapse
Affiliation(s)
- M Denislic
- University Institute of Clinical Neurophysiology Medical Center, Ljubljana, Slovenia
| | | | | | | | | |
Collapse
|
12
|
Greene PE, Fahn S. Use of botulinum toxin type F injections to treat torticollis in patients with immunity to botulinum toxin type A. Mov Disord 1993; 8:479-83. [PMID: 8232357 DOI: 10.1002/mds.870080411] [Citation(s) in RCA: 75] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/29/2023] Open
Abstract
Fifteen patients with torticollis who had been treated with repeated injections of botulinum toxin type A (botox A) developed antibodies to the toxin. This resulted in loss of benefit in the 13 patients who had improved with botox A injections and failure to develop muscle atrophy after injection in all 15 patients. Patients were then injected with botulinum toxin type F (botox F) in the same muscles that had been injected with botox A. Ten of the 15 improved after botox F injections, including 9 of the 12 patients who had improved with type A toxin. Six of 9 patients with pain had improvement in pain after botox F injections. Patients reported similar improvement with type F and type A toxins, but duration of benefit was approximately 3 months with type A and approximately 1 month with type F. Botox F is an effective treatment for torticollis in patients who are immune to botox A. The usefulness of type F toxin, however, is limited by short duration of benefit.
Collapse
Affiliation(s)
- P E Greene
- Dystonia Clinical Research Center, Columbia-Presbyterian Medical Center, New York, New York
| | | |
Collapse
|
13
|
Nightingale S, Orton D, Ratcliffe D, Skidmore S, Tosswill J, Desselberger U. Antenatal survey for the seroprevalence of HTLV-1 infections in the West Midlands, England. Epidemiol Infect 1993; 110:379-87. [PMID: 8472781 PMCID: PMC2272267 DOI: 10.1017/s0950268800068321] [Citation(s) in RCA: 22] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/31/2023] Open
Abstract
The sera of 3522 women who attended an antenatal clinic in Birmingham, England were tested anonymously for antibodies against HTLV-1. Samples from 5 women (0.14%) were positive, one serum showed indeterminate reactivity. Two of the women (0.06%) were born in the West Indies (of Afro-Caribbean ethnic origin), one (0.03%) in Africa (of African ethnic origin), and three (0.09%) were white Caucasian women born in the UK. Thus, HTLV-1 infection in pregnant women in the UK, though comparatively rare, is not negligible. As transmission of HTLV-1 to the newborn via breast milk has been observed and as seropositive mothers can be advised to refrain from breastfeeding or to treat their milk, the question of routine screening for HTLV-1 infection during antenatal care is discussed.
Collapse
Affiliation(s)
- S Nightingale
- Midland Centre for Neurosurgery and Neurology, Smethwick, West Midlands
| | | | | | | | | | | |
Collapse
|
14
|
Anderson TJ, Rivest J, Stell R, Steiger MJ, Cohen H, Thompson PD, Marsden CD. Botulinum Toxin Treatment of Spasmodic Torticollis. Med Chir Trans 1992. [DOI: 10.1177/014107689208500906] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
We reviewed the efficacy and adverse effects of repeated botulinum toxin injections into hyperactive neck muscles of 107 successive patients with spasmodic torticollis. They received 510 injection treatments over a median period of 15 months (range 3–42 months). One patient failed to benefit at all, but 101 (95%) patients reported considerable (moderate or excellent) benefit from at least one treatment. On a global subjective response rating, 93% of 429 treatments resulted in some improvement and 76% in moderate or excellent improvement. Pain reduction followed 89% of 190 treatments with moderate or excellent reduction after 66%. Median duration of benefit was 9 weeks. All torticollis types responded equally well and injections into two (or more) involved neck muscles were more effective than injection into a single muscle. The most frequent adverse effect was dysphagia, occurring after 44% of all treatments, but this was severe after only 2%. Antibodies to botulinum toxin were detected in the serum of three out of the five patients in whom loss of treatment efficacy occurred. We conclude that botulinum toxin treatment is the most effective available therapy for spasmodic torticollis and practical advice is provided for anyone wishing to set up the technique.
Collapse
Affiliation(s)
- T J Anderson
- University Department of Clinical Neurology, Institute of Neurology, The National Hospital, Queen Square, London WC1N 3BG
| | - J Rivest
- University Department of Clinical Neurology, Institute of Neurology, The National Hospital, Queen Square, London WC1N 3BG
| | - R Stell
- University Department of Clinical Neurology, Institute of Neurology, The National Hospital, Queen Square, London WC1N 3BG
| | - M J Steiger
- University Department of Clinical Neurology, Institute of Neurology, The National Hospital, Queen Square, London WC1N 3BG
| | - H Cohen
- Porton Developments Limited, Porton House, Vanwell Road, Maidenhead SL6 4UB
| | - P D Thompson
- University Department of Clinical Neurology, Institute of Neurology, The National Hospital, Queen Square, London WC1N 3BG
| | - C D Marsden
- University Department of Clinical Neurology, Institute of Neurology, The National Hospital, Queen Square, London WC1N 3BG
| |
Collapse
|
15
|
Toedter G, Pearlman S, Hofheinz D, Blakeslee J, Cockerell G, Dezzutti C, Yee J, Lal RB, Lairmore M. Development of a monoclonal antibody-based p24 capsid antigen detection assay for HTLV-I, HTLV-II, and STLV-I infection. AIDS Res Hum Retroviruses 1992; 8:527-32. [PMID: 1318063 DOI: 10.1089/aid.1992.8.527] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/26/2022] Open
Abstract
A monoclonal antibody-based antigen capture enzyme-linked immunosorbent assay (ELISA) was developed and employed to detect p24 capsid antigen from human T-cell lymphotropic viruses type I and II (HTLV-I, HTLV-II), simian T-cell lymphotropic virus type I (STLV-I)-infected cell lines, and from mononuclear cell cocultures of HTLV-infected humans and STLV-I infected monkeys. A monoclonal antibody specific for HTLV p24 and p53 capsid antigens was coated onto 96-well microtiter plates to capture HTLV/STLV antigen. Captured antigen was then detected by the addition of a polyclonal, biotinylated human anti-HTLV-I antibody, and color developed with tetramethyl benzidine/H2O2 substrate. As little as 15 pg/ml of HTLV-I p24 antigen could be detected in this assay. Culture supernatants from HTLV-I-infected cell lines (HUT-102, MT-2, C5/MJ, HTLV-II-infected cell lines (Mo-T, Mo-B, PanG 12.1, NRA) and STLV-I-infected cell lines (Matsu, NEPC M39) were all positive in the assay. In addition, p24 was detected from peripheral blood mononuclear cell (PBMC) cocultures of 8 of 8 (100%) HTLV-I diseased patients, 14 of 20 (70%) HTLV-I and HTLV-II-infected, asymptomatic persons, and 8 of 8 (100%) STLV-I-infected, asymptomatic monkeys. Culture supernatants of cells infected with human immunodeficiency virus type (HIV-1), simian immunodeficiency virus (SIV), Chlamydia trachomatis, cytomegalovirus (CMV), herpes simplex I and II (HSV), feline leukemia virus (FELV), bovine leukemia virus (BLV), and bovine immunodeficiency virus (BIV) were all negative. Similarly, normal human peripheral blood mononuclear cells and uninfected, transformed human T cells, were also negative in the assay.(ABSTRACT TRUNCATED AT 250 WORDS)
Collapse
Affiliation(s)
- G Toedter
- Coulter Immunology, Hialeah, Florida
| | | | | | | | | | | | | | | | | |
Collapse
|
16
|
Affiliation(s)
- J Jankovic
- Department of Neurology, Baylor College of Medicine, Houston, TX 77030
| | | |
Collapse
|
17
|
Yancey WB, Dolson LH, Oblon D, Smith LJ, Braylan R, Longley S, Williams RC. HTLV-I-associated adult T-cell leukemia/lymphoma presenting with nodular synovial masses. Am J Med 1990; 89:676-83. [PMID: 2239988 DOI: 10.1016/0002-9343(90)90189-k] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/30/2022]
Affiliation(s)
- W B Yancey
- Division of Rheumatology, University of Florida, College of Medicine, Gainesville
| | | | | | | | | | | | | |
Collapse
|
18
|
Armstrong MY, Hrdy DB, Carlson JR, Friedlaender JS. Prevalence of antibodies interactive with HTLV-I antigens in selected Solomon Islands populations. AMERICAN JOURNAL OF PHYSICAL ANTHROPOLOGY 1990; 81:465-70. [PMID: 2333936 DOI: 10.1002/ajpa.1330810403] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Abstract
Serum samples obtained in 1986 from healthy individuals in three distinct Solomon Islands populations were screened for antibodies to human lymphotropic virus type I (HTLV-I). One of the populations tested lives on the remote Polynesian outlier atoll, Ontong Java. The other two groups, the Baegu and the Lau, are Melanesians living on Malaita, the most populous of the larger Solomon Islands. Eighty-eight of a total of 601 (14.6%) sera tested were repeatably reactive in an enzyme-linked immunosorbent assay (ELISA) that uses as antigen a lysate of HTLV-I viral particles. The prevalence of antibodies interactive with HTLV-I viral particles. The prevalence of antibodies interactive with HTLV-I antigens varied among the three groups, ranging from 8.5% (16/188) in the Baegu, through 13% (7/54) in the Lau, to 18.1% (65/359) among the Ontong Java population. The specificity of the screening ELISA was confirmed by protein immunoblot. No serum samples were obtained from children under 9 years of age. Although 121 of the 601 sera came from children between the ages of 9 and 19, none of these were reactive in the HTLV-I ELISA. Starting in the third decade, the prevalence of HTLV-I seropositivity increased with age, from 8.8% (10/113) between the ages of 20 and 29 to a peak of 25.9% (15/58) and 25% (15/60) in the sixth and seventh decade, respectively. This age-specific prevalence pattern is strikingly similar to that which is seen in populations where HTLV-I infection is endemic.
Collapse
Affiliation(s)
- M Y Armstrong
- Department of Epidemiology, Yale University School of Medicine, New Haven, Connecticut 06510
| | | | | | | |
Collapse
|
19
|
Mowbray J, Mawson S, Chawira A, Skidmore S, Boxall E, Desselberger U, Nightingale S. Epidemiology of human T-cell leukaemia/lymphoma virus type 1 (HTLV-1) infections in a subpopulation of Afro-Caribbean origin in England. J Med Virol 1989; 29:289-95. [PMID: 2621455 DOI: 10.1002/jmv.1890290413] [Citation(s) in RCA: 22] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/01/2023]
Abstract
Epidemiological studies on neurological diseases in residents of Afro-Caribbean origin in the West Midlands region of England have identified eight patients with tropical spastic paraparesis (TSP), all of whom were found to be infected with human T-cell leukaemia/lymphoma virus type 1 (HTLV-1). The husband of one of the patients with TSP was also infected with HTLV-1 and had a T-cell lymphoma. In addition, six asymptomatic HTLV-1-infected first-degree relatives of the TSP patients have been found. By anonymous testing of over 700 sera obtained from individuals of Afro-Caribbean, African, or Asian ethnic origin, seven HTLV-1-infected individuals were detected, who were all immigrants from the Caribbean. Overall, these numbers yielded a seroprevalence of HTLV-1 infections of 3.4% among the immigrant population of Afro-Caribbean origin, which is comparable with the prevalence of HTLV-1 in Jamaica in an equivalent age and sex cohort. Sera were tested for HTLV-1 antibody by means of three different procedures: passive particle agglutination test (Serodia), indirect enzyme-labeled immunosorbent assay (ELISA; Dupont), and indirect immunofluorescence test (in-house, using HTLV-1-infected MT2 cells). The results of all three tests correlated very well with each other. HTLV-1 antibody titres in TSP patients were on the whole significantly higher than those of asymptomatic carriers, but some of the apparently healthy first-degree relatives and one anonymously tested individual had titres as high as most of the TSP patients.
Collapse
Affiliation(s)
- J Mowbray
- Regional Virus Laboratory, East Birmingham Hospital, England
| | | | | | | | | | | | | |
Collapse
|
20
|
Abstract
Retroviruses are single stranded RNA viruses that possess a unique enzyme, reverse transcriptase. This enzyme facilitates the synthesis of double stranded DNA intermediates able to integrate into the genome of the host cell. Although primarily a means of remaining latent, this integration can have the effect of transforming the cell to malignant growth, either by activation of growth control genes in cis or trans, or by insertion of an integrated oncogene. Malignant lymphomas caused by retroviruses occur in animals from mice to man, and have increasing economic and clinical significance. HTLV-1 is the causative agent of adult T-cell leukemia/lymphoma which is endemic in certain discrete locations of the world and has been implicated in a variety of other disorders. The fact that the virus seems to be spreading through groups of intravenous drug abusers in much the same way as the AIDS virus is a cause for concern.
Collapse
Affiliation(s)
- S G Norley
- Paul-Ehrlich-Institut, Frankfurt, Federal Republic of Germany
| | | |
Collapse
|
21
|
Sarin PS, Rodgers-Johnson P, Sun DK, Thornton AH, Morgan OS, Gibbs WN, Mora C, McKhann G, Gajdusek DC, Gibbs CJ. Comparison of a human T-cell lymphotropic virus type I strain from cerebrospinal fluid of a Jamaican patient with tropical spastic paraparesis with a prototype human T-cell lymphotropic virus type I. Proc Natl Acad Sci U S A 1989; 86:2021-5. [PMID: 2467295 PMCID: PMC286838 DOI: 10.1073/pnas.86.6.2021] [Citation(s) in RCA: 19] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/01/2023] Open
Abstract
The isolation and characterization of a human T-cell lymphotropic retrovirus related to human T-cell lymphotropic virus type I (HTLV-I) from cerebrospinal fluid of a Jamaican patient with tropical spastic paraparesis is described. The virus isolate is a typical type C retrovirus as seen by electron microscopy and is related to prototype HTLV-I isolated from patients with adult T-cell leukemia but is not identical to this prototype HTLV-I as seen by restriction enzyme mapping.
Collapse
Affiliation(s)
- P S Sarin
- Laboratory of Tumor Cell Biology, National Cancer Institute, Bethesda, MD 20892
| | | | | | | | | | | | | | | | | | | |
Collapse
|
22
|
Grimaldi LM, Roos RP, Devare SG, Casey JM, Maruo Y, Hamada T, Tashiro K. HTLV-I-associated myelopathy: oligoclonal immunoglobulin G bands contain anti-HTLV-I p24 antibody. Ann Neurol 1988; 24:727-31. [PMID: 3207356 DOI: 10.1002/ana.410240606] [Citation(s) in RCA: 40] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/04/2023]
Abstract
Human T-cell lymphotropic virus type I (HTLV-I)-associated myelopathy (HAM) and tropical spastic paraparesis belong to a new group of neurological diseases associated with retroviral infection. An HTLV-I-like virus has recently been implicated in multiple sclerosis as well. We studied paired cerebrospinal fluid and serum specimens from HAM and multiple sclerosis patients by isoelectric focusing and an isoelectric focusing HTLV-I p24 overlay technique to clarify the role of HTLV-I in these diseases. We detected oligoclonal bands by isoelectric focusing with silver-staining in cerebrospinal fluid, but not serum, from all 5 HAM and all 9 multiple sclerosis patients. An isoelectric focusing HTLV-I p24 overlay technique demonstrated anti-p24 antibody in HAM cerebrospinal fluid at a different pI distribution than that seen in paired serum, indicating local synthesis of anti-p24 antibody within the central nervous system. Oligoclonal bands in HAM cerebrospinal fluid corresponded in pI distribution to anti-p24 antibody activity, suggesting the presence of an ongoing HTLV-I infection in the central nervous system. Multiple sclerosis patients had no evidence of anti-HTLV-I activity by p24 radioimmunoprecipitation assay, Western immunoblots, or isoelectric focusing HTLV-I p24 overlay analysis. Our data support a role for HTLV-I as an etiological agent in HAM, but not in multiple sclerosis.
Collapse
Affiliation(s)
- L M Grimaldi
- University of Chicago, Department of Neurology, IL 60637
| | | | | | | | | | | | | |
Collapse
|
23
|
Sarin PS, Gallo RC. Lymphotropic retroviruses of animals and man. ADVANCES IN VETERINARY SCIENCE AND COMPARATIVE MEDICINE 1988; 32:227-50. [PMID: 2847502 DOI: 10.1016/b978-0-12-039232-2.50012-8] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/02/2023]
Affiliation(s)
- P S Sarin
- Laboratory of Tumor Cell Biology, National Cancer Institute, Bethesda, Maryland 20892
| | | |
Collapse
|